Home The Word Brain	My Amedeo FAQ Privacy About	Flying Publisher
	COVID-19: Daily Top 10 Papers

Lung Cancer

Free Subscription Articles published in Lancet Oncol Retrieve available abstracts of 135 articles: HTML format

Single Articles

March 2021
1. GOLDMAN JW, Paz-Ares L
   Combination treatment options for small-cell lung cancer - Authors' reply.
   Lancet Oncol. 2021;22:e84.
   PubMed    
   
   
   
2. HORITA N, Katakura S, Takeshi K
   Combination treatment options for small-cell lung cancer.
   Lancet Oncol. 2021;22:e83.
   PubMed    
   
   
   
3. GRONBERG BH, Killingberg KT, Flotten O, Brustugun OT, et al
   High-dose versus standard-dose twice-daily thoracic radiotherapy for patients with limited stage small-cell lung cancer: an open-label, randomised, phase 2 trial.
   Lancet Oncol. 2021;22:321-331.
   PubMed     Abstract available
   
   
   
4. SENAN S
   The elusive pursuit of progress in limited stage small-cell lung cancer.
   Lancet Oncol. 2021;22:290-291.
   PubMed    
   
   
   February 2021
5. PASS HI
   SMART: logical radiotherapy and surgery beyond MARS.
   Lancet Oncol. 2021;22:156-157.
   PubMed    
   
   
   
6. CHO BCJ, Donahoe L, Bradbury PA, Leighl N, et al
   Surgery for malignant pleural mesothelioma after radiotherapy (SMART): final results from a single-centre, phase 2 trial.
   Lancet Oncol. 2021;22:190-197.
   PubMed     Abstract available
   
   
   January 2021
7. PAZ-ARES L, Ciuleanu TE, Cobo M, Schenker M, et al
   First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open-label, phase 3 trial.
   Lancet Oncol. 2021 Jan 18. pii: S1470-2045(20)30641.
   PubMed     Abstract available
   
   
   
8. PASSARO A, Attili I, de Marinis F
   CheckMate 9LA: broadening treatment options for patients with non-small-cell lung cancer.
   Lancet Oncol. 2021 Jan 18. pii: S1470-2045(20)30701.
   PubMed    
   
   
   
9. CORREA RJM, Palma DA
   Should stereotactic ablative body radiotherapy be the standard of care in oligometastatic cancer?
   Lancet Oncol. 2021;22:6-8.
   PubMed    
   
   
   December 2020
10. GOLDMAN JW, Dvorkin M, Chen Y, Reinmuth N, et al
    Durvalumab, with or without tremelimumab, plus platinum-etoposide versus platinum-etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial.
    Lancet Oncol. 2020 Dec 4. pii: S1470-2045(20)30539.
    PubMed     Abstract available
    
    
    
11. CHOUAID C, Monnet I, Baize N
    Carboplatin plus etoposide for sensitive relapsed small-cell lung cancer - Authors' reply.
    Lancet Oncol. 2020;21:e546.
    PubMed    
    
    
    
12. HORITA N, Chen H, Takeshi K
    Carboplatin plus etoposide for sensitive relapsed small-cell lung cancer.
    Lancet Oncol. 2020;21:e545.
    PubMed    
    
    
    
13. SUERO-ABREU GA, Wooley RH, Barajas-Ochoa A, Lovoulos C, et al
    Spontaneous pneumothorax secondary to an endometrial stromal sarcoma.
    Lancet Oncol. 2020;21:e589.
    PubMed    
    
    
    November 2020
14. GOURD E
    Lung cancer control in the UK hit badly by COVID-19 pandemic.
    Lancet Oncol. 2020 Nov 12. pii: S1470-2045(20)30691.
    PubMed    
    
    
    October 2020
15. REDMAN MW, Papadimitrakopoulou VA, Minichiello K, Hirsch FR, et al
    Biomarker-driven therapies for previously treated squamous non-small-cell lung cancer (Lung-MAP SWOG S1400): a biomarker-driven master protocol.
    Lancet Oncol. 2020 Oct 27. pii: S1470-2045(20)30475.
    PubMed     Abstract available
    
    
    September 2020
16. PROVENCIO M, Nadal E, Insa A, Garcia-Campelo MR, et al
    Neoadjuvant chemotherapy and nivolumab in resectable non-small-cell lung cancer (NADIM): an open-label, multicentre, single-arm, phase 2 trial.
    Lancet Oncol. 2020 Sep 24. pii: S1470-2045(20)30453.
    PubMed     Abstract available
    
    
    
17. BAIZE N, Monnet I, Greillier L, Geier M, et al
    Carboplatin plus etoposide versus topotecan as second-line treatment for patients with sensitive relapsed small-cell lung cancer: an open-label, multicentre, randomised, phase 3 trial.
    Lancet Oncol. 2020;21:1224-1233.
    PubMed     Abstract available
    
    
    
18. ARRIETA O, Lara-Mejia L, Zatarain-Barron ZL
    Carboplatin plus etoposide or topotecan for small-cell lung cancer.
    Lancet Oncol. 2020;21:1132-1134.
    PubMed    
    
    
    
19. NOWAK AK, Lesterhuis WJ, Kok PS, Brown C, et al
    Durvalumab with first-line chemotherapy in previously untreated malignant pleural mesothelioma (DREAM): a multicentre, single-arm, phase 2 trial with a safety run-in.
    Lancet Oncol. 2020;21:1213-1223.
    PubMed     Abstract available
    
    
    July 2020
20. MARINGE C, Spicer J, Morris M, Purushotham A, et al
    The impact of the COVID-19 pandemic on cancer deaths due to delays in diagnosis in England, UK: a national, population-based, modelling study.
    Lancet Oncol. 2020 Jul 20. pii: S1470-2045(20)30388.
    PubMed     Abstract available
    
    
    
21. RAMELLA S, D'Angelillo RM
    Proton beam or photon beam radiotherapy in the treatment of non-small-cell lung cancer.
    Lancet Oncol. 2020;21:873-875.
    PubMed    
    
    
    June 2020
22. NESTLE U, Schimek-Jasch T, Konig J
    Less is more? Imaging-based target volume reduction - Authors' reply.
    Lancet Oncol. 2020;21:e303.
    PubMed    
    
    
    
23. BLAIS E, Troussier I
    Less is more? Imaging-based target volume reduction.
    Lancet Oncol. 2020;21:e302.
    PubMed    
    
    
    May 2020
24. ROSELL R, Ito M
    Neoadjuvant atezolizumab plus chemotherapy in resectable non-small-cell lung cancer.
    Lancet Oncol. 2020 May 7. pii: S1470-2045(20)30146.
    PubMed    
    
    
    
25. SHU CA, Gainor JF, Awad MM, Chiuzan C, et al
    Neoadjuvant atezolizumab and chemotherapy in patients with resectable non-small-cell lung cancer: an open-label, multicentre, single-arm, phase 2 trial.
    Lancet Oncol. 2020 May 7. pii: S1470-2045(20)30140.
    PubMed     Abstract available
    
    
    
26. GOLDBERG SB, Schalper KA, Gettinger SN, Mahajan A, et al
    Pembrolizumab for management of patients with NSCLC and brain metastases: long-term results and biomarker analysis from a non-randomised, open-label, phase 2 trial.
    Lancet Oncol. 2020;21:655-663.
    PubMed     Abstract available
    
    
    April 2020
27. BARLESI F, Tomasini P
    Non-small-cell lung cancer brain metastases and PD-(L)1 immune checkpoint inhibitors.
    Lancet Oncol. 2020 Apr 3. pii: S1470-2045(20)30207.
    PubMed    
    
    
    March 2020
28. TRIGO J, Subbiah V, Besse B, Moreno V, et al
    Lurbinectedin as second-line treatment for patients with small-cell lung cancer: a single-arm, open-label, phase 2 basket trial.
    Lancet Oncol. 2020 Mar 27. pii: S1470-2045(20)30068.
    PubMed     Abstract available
    
    
    
29. ARRIETA O, Zatarain-Barron ZL, Cardona AF
    New opportunities in a challenging disease: lurbinectedin for relapsed small-cell lung cancer.
    Lancet Oncol. 2020 Mar 27. pii: S1470-2045(20)30097.
    PubMed    
    
    
    
30. REALE ML, Di Maio M
    Quality of life in patients with lung cancer: the way forward.
    Lancet Oncol. 2020 Mar 23. pii: S1470-2045(20)30151.
    PubMed    
    
    
    
31. KOLLER M, Shamieh O, Hjermstad MJ, Hornslien K, et al
    Psychometric properties of the updated EORTC module for assessing quality of life in patients with lung cancer (QLQ-LC29): an international, observational field study.
    Lancet Oncol. 2020 Mar 23. pii: S1470-2045(20)30093.
    PubMed     Abstract available
    
    
    
32. NESTLE U, Schimek-Jasch T, Kremp S, Schaefer-Schuler A, et al
    Imaging-based target volume reduction in chemoradiotherapy for locally advanced non-small-cell lung cancer (PET-Plan): a multicentre, open-label, randomised, controlled trial.
    Lancet Oncol. 2020 Mar 12. pii: S1470-2045(20)30013.
    PubMed     Abstract available
    
    
    
33. FAIVRE-FINN C
    Less is more in radiotherapy target volume planning: lessons from the PET-plan trial.
    Lancet Oncol. 2020 Mar 12. pii: S1470-2045(20)30108.
    PubMed    
    
    
    February 2020
34. GARASSINO MC, Gadgeel S, Esteban E, Felip E, et al
    Patient-reported outcomes following pembrolizumab or placebo plus pemetrexed and platinum in patients with previously untreated, metastatic, non-squamous non-small-cell lung cancer (KEYNOTE-189): a multicentre, double-blind, randomised, placebo-contro
    Lancet Oncol. 2020 Feb 6. pii: S1470-2045(19)30801.
    PubMed     Abstract available
    
    
    
35. FUNG AS, Leighl NB
    Advancing the systemic therapy of lung cancer: quality or quantity?
    Lancet Oncol. 2020 Feb 6. pii: S1470-2045(20)30076.
    PubMed    
    
    
    
36. SEQUIST LV, Han JY, Ahn MJ, Cho BC, et al
    Osimertinib plus savolitinib in patients with EGFR mutation-positive, MET-amplified, non-small-cell lung cancer after progression on EGFR tyrosine kinase inhibitors: interim results from a multicentre, open-label, phase 1b study.
    Lancet Oncol. 2020 Feb 3. pii: S1470-2045(19)30785.
    PubMed     Abstract available
    
    
    
37. SCHMID S, Fruh M, Peters S
    Targeting MET in EGFR resistance in non-small-cell lung cancer-ready for daily practice?
    Lancet Oncol. 2020 Feb 3. pii: S1470-2045(19)30859.
    PubMed    
    
    
    
38. LASSEN U
    Entrectinib for ROS1 fusion-positive NSCLC and NTRK fusion-positive solid tumours.
    Lancet Oncol. 2020;21:193-194.
    PubMed    
    
    
    
39. MIAN I, Padiernos E, Hassan R, Ghafoor A, et al
    Orbital metastases from malignant mesothelioma.
    Lancet Oncol. 2020;21:e117.
    PubMed    
    
    
    January 2020
40. DE GOOIJER CJ, Burgers JA
    Tumour Treating Fields for mesothelioma.
    Lancet Oncol. 2020;21:e9.
    PubMed    
    
    
    
41. BARBARINO M, Bottaro M, Luzzi L, Giordano A, et al
    Tumour Treating Fields for mesothelioma.
    Lancet Oncol. 2020;21:e8.
    PubMed    
    
    
    
42. CERESOLI GL, Gianoncelli L, Grosso F
    Tumour Treating Fields for mesothelioma - Authors' reply.
    Lancet Oncol. 2020;21:e10.
    PubMed    
    
    
    
43. GOURD E
    Osimertinib for leptomeningeal metastases in NSCLC.
    Lancet Oncol. 2020;21:e17.
    PubMed    
    
    
    
44. GOURD E
    Overall survival with osimertinib in untreated NSCLC.
    Lancet Oncol. 2020;21:e15.
    PubMed    
    
    
    December 2019
45. DRILON A, Siena S, Dziadziuszko R, Barlesi F, et al
    Entrectinib in ROS1 fusion-positive non-small-cell lung cancer: integrated analysis of three phase 1-2 trials.
    Lancet Oncol. 2019 Dec 11. pii: S1470-2045(19)30690.
    PubMed     Abstract available
    
    
    October 2019
46. DURUISSEAUX M
    Lorlatinib: a new treatment option for ROS1-positive lung cancer.
    Lancet Oncol. 2019 Oct 25. pii: S1470-2045(19)30716.
    PubMed    
    
    
    
47. SHAW AT, Solomon BJ, Chiari R, Riely GJ, et al
    Lorlatinib in advanced ROS1-positive non-small-cell lung cancer: a multicentre, open-label, single-arm, phase 1-2 trial.
    Lancet Oncol. 2019 Oct 25. pii: S1470-2045(19)30655.
    PubMed     Abstract available
    
    
    
48. HUI R, Ozguroglu M, Villegas A, Daniel D, et al
    Patient-reported outcomes with durvalumab after chemoradiotherapy in stage III, unresectable non-small-cell lung cancer (PACIFIC): a randomised, controlled, phase 3 study.
    Lancet Oncol. 2019 Oct 7. pii: S1470-2045(19)30519.
    PubMed     Abstract available
    
    
    
49. ANOTA A, Westeel V
    Quality of life with durvalumab in stage III non-small-cell lung cancer.
    Lancet Oncol. 2019 Oct 7. pii: S1470-2045(19)30643.
    PubMed    
    
    
    
50. NAKAGAWA K, Garon EB, Seto T, Nishio M, et al
    Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): a randomised, double-blind, placebo-controlled, phase 3 trial.
    Lancet Oncol. 2019 Oct 4. pii: S1470-2045(19)30634.
    PubMed     Abstract available
    
    
    
51. ROSELL R, Pedraz-Valdunciel C
    Are neutralising anti-VEGF or VEGFR2 antibodies necessary in the treatment of EGFR-mutated non-small-cell lung cancer?
    Lancet Oncol. 2019 Oct 4. pii: S1470-2045(19)30636.
    PubMed    
    
    
    
52. AHN MJ, Han JY, Lee KH, Kim SW, et al
    Lazertinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: results from the dose escalation and dose expansion parts of a first-in-human, open-label, multicentre, phase 1-2 study.
    Lancet Oncol. 2019 Oct 3. pii: S1470-2045(19)30504.
    PubMed     Abstract available
    
    
    
53. FIERO MH, Roydhouse JK, Vallejo J, King-Kallimanis BL, et al
    US Food and Drug Administration review of statistical analysis of patient-reported outcomes in lung cancer clinical trials approved between January, 2008, and December, 2017.
    Lancet Oncol. 2019;20:e582-e589.
    PubMed     Abstract available
    
    
    September 2019
54. CAPPUZZO F, West H
    Chemoimmunotherapy for stage IV non-small-cell lung cancer - Authors' reply.
    Lancet Oncol. 2019;20:e467.
    PubMed    
    
    
    
55. UPRETY D
    Chemoimmunotherapy for stage IV non-small-cell lung cancer.
    Lancet Oncol. 2019;20:e466.
    PubMed    
    
    
    August 2019
56. DAS M
    Nelfinavir with concurrent chemoradiotherapy in NSCLC.
    Lancet Oncol. 2019 Aug 30. pii: S1470-2045(19)30567.
    PubMed    
    
    
    
57. ANTONIA SJ, Borghaei H, Ramalingam SS, Horn L, et al
    Four-year survival with nivolumab in patients with previously treated advanced non-small-cell lung cancer: a pooled analysis.
    Lancet Oncol. 2019 Aug 14. pii: S1470-2045(19)30407.
    PubMed     Abstract available
    
    
    
58. SOUQUET PJ, Couraud S
    Immune checkpoint inhibitors: a game changer for metastatic non-small-cell lung cancer.
    Lancet Oncol. 2019 Aug 14. pii: S1470-2045(19)30508.
    PubMed    
    
    
    July 2019
59. HERBST RS, Arkenau HT, Santana-Davila R, Calvo E, et al
    Ramucirumab plus pembrolizumab in patients with previously treated advanced non-small-cell lung cancer, gastro-oesophageal cancer, or urothelial carcinomas (JVDF): a multicohort, non-randomised, open-label, phase 1a/b trial.
    Lancet Oncol. 2019 Jul 10. pii: S1470-2045(19)30458.
    PubMed     Abstract available
    
    
    June 2019
60. LUO YH, Luo L, Wampfler JA, Wang Y, et al
    5-year overall survival in patients with lung cancer eligible or ineligible for screening according to US Preventive Services Task Force criteria: a prospective, observational cohort study.
    Lancet Oncol. 2019 Jun 26. pii: S1470-2045(19)30329.
    PubMed     Abstract available
    
    
    
61. BERG CD
    Improving selection of individuals into lung cancer screening programmes.
    Lancet Oncol. 2019 Jun 26. pii: S1470-2045(19)30411.
    PubMed    
    
    
    May 2019
62. LI Y, Wu YL
    The second wave of checkpoint inhibitors with chemotherapy for advanced non-small-cell lung cancer.
    Lancet Oncol. 2019 May 20. pii: S1470-2045(19)30148.
    PubMed    
    
    
    
63. WEST H, McCleod M, Hussein M, Morabito A, et al
    Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3
    Lancet Oncol. 2019 May 20. pii: S1470-2045(19)30167.
    PubMed     Abstract available
    
    
    April 2019
64. JIANG Z, Li W, Hu X, Zhang Q, et al
    Tucidinostat plus exemestane for postmenopausal patients with advanced, hormone receptor-positive breast cancer (ACE): a randomised, double-blind, placebo-controlled, phase 3 trial.
    Lancet Oncol. 2019 Apr 26. pii: S1470-2045(19)30164.
    PubMed     Abstract available
    
    
    
65. SAITO H, Fukuhara T, Furuya N, Watanabe K, et al
    Erlotinib plus bevacizumab versus erlotinib alone in patients with EGFR-positive advanced non-squamous non-small-cell lung cancer (NEJ026): interim analysis of an open-label, randomised, multicentre, phase 3 trial.
    Lancet Oncol. 2019 Apr 8. pii: S1470-2045(19)30035.
    PubMed     Abstract available
    
    
    February 2019
66. ALSHAFA F, Palma D
    CHISELing a path forward in the treatment of early-stage non-small-cell lung cancer.
    Lancet Oncol. 2019 Feb 12. pii: S1470-2045(18)30953.
    PubMed    
    
    
    
67. BALL D, Mai GT, Vinod S, Babington S, et al
    Stereotactic ablative radiotherapy versus standard radiotherapy in stage 1 non-small-cell lung cancer (TROG 09.02 CHISEL): a phase 3, open-label, randomised controlled trial.
    Lancet Oncol. 2019 Feb 12. pii: S1470-2045(18)30896.
    PubMed     Abstract available
    
    
    November 2018
68. SOLOMON BJ, Besse B, Bauer TM, Felip E, et al
    Lorlatinib in patients with ALK-positive non-small-cell lung cancer: results from a global phase 2 study.
    Lancet Oncol. 2018 Nov 6. pii: S1470-2045(18)30649.
    PubMed     Abstract available
    
    
    September 2018
69. ROSELL R, Karachaliou N
    Avelumab in non-small-cell lung cancer.
    Lancet Oncol. 2018 Sep 21. pii: S1470-2045(18)30683.
    PubMed    
    
    
    
70. BARLESI F, Vansteenkiste J, Spigel D, Ishii H, et al
    Avelumab versus docetaxel in patients with platinum-treated advanced non-small-cell lung cancer (JAVELIN Lung 200): an open-label, randomised, phase 3 study.
    Lancet Oncol. 2018 Sep 21. pii: S1470-2045(18)30673.
    PubMed     Abstract available
    
    
    
71. BLACKHALL F, Frese KK, Simpson K, Kilgour E, et al
    Will liquid biopsies improve outcomes for patients with small-cell lung cancer?
    Lancet Oncol. 2018;19:e470-e481.
    PubMed     Abstract available
    
    
    August 2018
72. HIOM SC, Kumar HS, Swanton C, Baldwin DR, et al
    Lung cancer in the UK: addressing geographical inequality and late diagnosis.
    Lancet Oncol. 2018;19:1015-1017.
    PubMed    
    
    
    July 2018
73. GLANVILLE AR, Wilson BE
    Lung transplantation for non-small cell lung cancer and multifocal bronchioalveolar cell carcinoma.
    Lancet Oncol. 2018;19:e351-e358.
    PubMed     Abstract available
    
    
    
74. BAAS P, Burgers S
    Malignant pleural effusions: will PROMISE make its name true?
    Lancet Oncol. 2018;19:853-855.
    PubMed    
    
    
    
75. LUCAS C
    Miracle mineral or mesothelioma: cancer and asbestos in the USA.
    Lancet Oncol. 2018;19:868.
    PubMed    
    
    
    June 2018
76. GOURD E
    Lung cancer incidence higher in US women than men.
    Lancet Oncol. 2018 Jun 1. pii: S1470-2045(18)30422.
    PubMed    
    
    
    
77. GREGORC V, Gaafar RM, Favaretto A, Grossi F, et al
    NGR-hTNF in combination with best investigator choice in previously treated malignant pleural mesothelioma (NGR015): a randomised, double-blind, placebo-controlled phase 3 trial.
    Lancet Oncol. 2018;19:799-811.
    PubMed     Abstract available
    
    
    April 2018
78. ROLFO C, Smits ELJ
    Combining top-ranked immunotherapeutics in lung cancer.
    Lancet Oncol. 2018 Apr 5. pii: S1470-2045(18)30186.
    PubMed    
    
    
    
79. WRANGLE JM, Velcheti V, Patel MR, Garrett-Mayer E, et al
    ALT-803, an IL-15 superagonist, in combination with nivolumab in patients with metastatic non-small cell lung cancer: a non-randomised, open-label, phase 1b trial.
    Lancet Oncol. 2018 Apr 5. pii: S1470-2045(18)30148.
    PubMed     Abstract available
    
    
    March 2018
80. LIN JJ, Gainor JF
    ATLANTIC: a sea change in immunotherapy for oncogene-driven lung cancer?
    Lancet Oncol. 2018 Mar 12. pii: S1470-2045(18)30160.
    PubMed    
    
    
    
81. GARASSINO MC, Cho BC, Kim JH, Mazieres J, et al
    Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study.
    Lancet Oncol. 2018 Mar 12. pii: S1470-2045(18)30144.
    PubMed     Abstract available
    
    
    
82. FIELD JK, Heuvelmans MA, Devaraj A, Heussel CP, et al
    Low-dose CT for lung cancer screening - Authors' reply.
    Lancet Oncol. 2018;19:e135-e136.
    PubMed    
    
    
    
83. BACH PB, Brawley OW, Silvestri GA
    Low-dose CT for lung cancer screening.
    Lancet Oncol. 2018;19:e133-e134.
    PubMed    
    
    
    
84. RUANO-RAVINA A, Perez-Rios M, Casan-Clara P, Provencio-Pulla M, et al
    Low-dose CT for lung cancer screening.
    Lancet Oncol. 2018;19:e131-e132.
    PubMed    
    
    
    
85. WU YL, Zhong WZ
    Adjuvant therapy for resected EGFR-mutant non-small-cell lung cancer - Authors' reply.
    Lancet Oncol. 2018;19:e127.
    PubMed    
    
    
    
86. ROSELL R, Karachaliou N
    Adjuvant therapy for resected EGFR-mutant non-small-cell lung cancer.
    Lancet Oncol. 2018;19:e126.
    PubMed    
    
    
    
87. MA JA, Jiang S, Hu C, Xie Y, et al
    Adjuvant therapy for resected EGFR-mutant non-small-cell lung cancer.
    Lancet Oncol. 2018;19:e125.
    PubMed    
    
    
    
88. WU F, Liu X, Ma JA, Gao Y, et al
    Adjuvant therapy for resected EGFR-mutant non-small-cell lung cancer.
    Lancet Oncol. 2018;19:e124.
    PubMed    
    
    
    
89. SCHERPEREEL A, Wallyn F, Albelda SM, Munck C, et al
    Novel therapies for malignant pleural mesothelioma.
    Lancet Oncol. 2018;19:e161-e172.
    PubMed     Abstract available
    
    
    February 2018
90. ILEANA-DUMBRAVA E, Subbiah V
    Autoimmune hypophysitis.
    Lancet Oncol. 2018;19:e123.
    PubMed    
    
    
    January 2018
91. CHENG H, Perez-Soler R
    Leptomeningeal metastases in non-small-cell lung cancer.
    Lancet Oncol. 2018;19:e43-e55.
    PubMed     Abstract available
    
    
    
92. WU YL, Mok TS
    Dacomitinib in NSCLC: a positive trial with little clinical impact - Authors' reply.
    Lancet Oncol. 2018;19:e5.
    PubMed    
    
    
    
93. ADDEO A
    Dacomitinib in NSCLC: a positive trial with little clinical impact.
    Lancet Oncol. 2018;19:e4.
    PubMed    
    
    
    
94. NG TL, Camidge DR
    Lung cancer's real adjuvant EGFR targeted therapy questions.
    Lancet Oncol. 2018;19:15-17.
    PubMed    
    
    
    
95. PIRKER R
    EGFR monoclonal antibody biomarkers in advanced NSCLC: from translational research to clinical implementation.
    Lancet Oncol. 2018;19:10-12.
    PubMed    
    
    
    
96. STIRRUPS R
    Osimertinib improves progression-free survival in NSCLC.
    Lancet Oncol. 2018;19:e10.
    PubMed    
    
    
    
97. GOURD E
    Durvalumab boosts progression-free survival in NSCLC.
    Lancet Oncol. 2018;19:e11.
    PubMed    
    
    
    
98. ZHONG WZ, Wang Q, Mao WM, Xu ST, et al
    Gefitinib versus vinorelbine plus cisplatin as adjuvant treatment for stage II-IIIA (N1-N2) EGFR-mutant NSCLC (ADJUVANT/CTONG1104): a randomised, open-label, phase 3 study.
    Lancet Oncol. 2018;19:139-148.
    PubMed     Abstract available
    
    
    
99. HERBST RS, Redman MW, Kim ES, Semrad TJ, et al
    Cetuximab plus carboplatin and paclitaxel with or without bevacizumab versus carboplatin and paclitaxel with or without bevacizumab in advanced NSCLC (SWOG S0819): a randomised, phase 3 study.
    Lancet Oncol. 2018;19:101-114.
    PubMed     Abstract available
    
    
    December 2017
100. OUDKERK M, Devaraj A, Vliegenthart R, Henzler T, et al
     European position statement on lung cancer screening.
     Lancet Oncol. 2017;18:e754-e766.
     PubMed     Abstract available
     
     
     
101. EMERY JD, Mitchell PL
     Lung cancer in Asian women and health system implications for Australia.
     Lancet Oncol. 2017;18:1570-1571.
     PubMed    
     
     
     
102. BRAHMER JR, Rodriguez-Abreu D, Robinson AG, Hui R, et al
     Health-related quality-of-life results for pembrolizumab versus chemotherapy in advanced, PD-L1-positive NSCLC (KEYNOTE-024): a multicentre, international, randomised, open-label phase 3 trial.
     Lancet Oncol. 2017;18:1600-1609.
     PubMed     Abstract available
     
     
     
103. FEROLLA P, Brizzi MP, Meyer T, Mansoor W, et al
     Efficacy and safety of long-acting pasireotide or everolimus alone or in combination in patients with advanced carcinoids of the lung and thymus (LUNA): an open-label, multicentre, randomised, phase 2 trial.
     Lancet Oncol. 2017;18:1652-1664.
     PubMed     Abstract available
     
     
     November 2017
104. WEISS J
     Bevacizumab in adjuvant treatment of non-small-cell lung cancer.
     Lancet Oncol. 2017 Nov 9. pii: S1470-2045(17)30843.
     PubMed    
     
     
     
105. WAKELEE HA, Dahlberg SE, Keller SM, Tester WJ, et al
     Adjuvant chemotherapy with or without bevacizumab in patients with resected non-small-cell lung cancer (E1505): an open-label, multicentre, randomised, phase 3 trial.
     Lancet Oncol. 2017 Nov 9. pii: S1470-2045(17)30691.
     PubMed     Abstract available
     
     
     October 2017
106. SHAW AT, Felip E, Bauer TM, Besse B, et al
     Lorlatinib in non-small-cell lung cancer with ALK or ROS1 rearrangement: an international, multicentre, open-label, single-arm first-in-man phase 1 trial.
     Lancet Oncol. 2017 Oct 23. pii: S1470-2045(17)30680.
     PubMed     Abstract available
     
     
     
107. DE KONING HJ
     Lung cancer screening and its continuous risk assessment.
     Lancet Oncol. 2017 Oct 16. pii: S1470-2045(17)30730.
     PubMed    
     
     
     
108. TAMMEMAGI MC, Schmidt H, Martel S, McWilliams A, et al
     Participant selection for lung cancer screening by risk modelling (the Pan-Canadian Early Detection of Lung Cancer [PanCan] study): a single-arm, prospective study.
     Lancet Oncol. 2017 Oct 16. pii: S1470-2045(17)30597.
     PubMed     Abstract available
     
     
     
109. FAIVRE-FINN C, Ryder WD, Blackhall F
     Is it time to convert the frequency of radiotherapy in small-cell lung cancer? - Authors' reply.
     Lancet Oncol. 2017;18:e556.
     PubMed    
     
     
     
110. EZE C, Roengvoraphoj O, Dantes M, Manapov F, et al
     Is it time to convert the frequency of radiotherapy in small-cell lung cancer?
     Lancet Oncol. 2017;18:e555.
     PubMed    
     
     
     
111. MITIN T, Farrell M, Holland J, Cetnar J, et al
     Is it time to convert the frequency of radiotherapy in small-cell lung cancer?
     Lancet Oncol. 2017;18:e554.
     PubMed    
     
     
     
112. ZENG H, Yu J, Yuan S
     Is it time to convert the frequency of radiotherapy in small-cell lung cancer?
     Lancet Oncol. 2017;18:e553.
     PubMed    
     
     
     
113. VAN ZANDWIJK N, Pavlakis N, Kao SC, Linton A, et al
     Safety and activity of microRNA-loaded minicells in patients with recurrent malignant pleural mesothelioma: a first-in-man, phase 1, open-label, dose-escalation study.
     Lancet Oncol. 2017;18:1386-1396.
     PubMed     Abstract available
     
     
     
114. PAVEL ME, Singh S, Strosberg JR, Bubuteishvili-Pacaud L, et al
     Health-related quality of life for everolimus versus placebo in patients with advanced, non-functional, well-differentiated gastrointestinal or lung neuroendocrine tumours (RADIANT-4): a multicentre, randomised, double-blind, placebo-controlled, phase
     Lancet Oncol. 2017;18:1411-1422.
     PubMed     Abstract available
     
     
     September 2017
115. BRUECKL WM
     Treatment choice in EGFR-mutant non-small-cell lung cancer.
     Lancet Oncol. 2017 Sep 25. pii: S1470-2045(17)30684.
     PubMed    
     
     
     
116. WU YL, Cheng Y, Zhou X, Lee KH, et al
     Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial.
     Lancet Oncol. 2017 Sep 25. pii: S1470-2045(17)30608.
     PubMed     Abstract available
     
     
     
117. PLANCHARD D, Smit EF, Groen HJM, Mazieres J, et al
     Dabrafenib plus trametinib in patients with previously untreated BRAFV600E-mutant metastatic non-small-cell lung cancer: an open-label, phase 2 trial.
     Lancet Oncol. 2017 Sep 8. pii: S1470-2045(17)30679.
     PubMed     Abstract available
     
     
     
118. PERROT M, Wu L, Wu M, Cho BCJ, et al
     Radiotherapy for the treatment of malignant pleural mesothelioma.
     Lancet Oncol. 2017;18:e532-e542.
     PubMed     Abstract available
     
     
     
119. MAIO M, Scherpereel A, Calabro L, Aerts J, et al
     Tremelimumab as second-line or third-line treatment in relapsed malignant mesothelioma (DETERMINE): a multicentre, international, randomised, double-blind, placebo-controlled phase 2b trial.
     Lancet Oncol. 2017;18:1261-1273.
     PubMed     Abstract available
     
     
     July 2017
120. AKAMATSU H, Takahashi T, Yamamoto N
     Prophylactic cranial irradiation in small-cell lung cancer - Authors' reply.
     Lancet Oncol. 2017;18:e369.
     PubMed    
     
     
     
121. FAN X, Liang F, Zhu J
     Prophylactic cranial irradiation in small-cell lung cancer.
     Lancet Oncol. 2017;18:e368.
     PubMed    
     
     
     
122. WEISS GJ, Lohinai Z
     Prophylactic cranial irradiation in small-cell lung cancer.
     Lancet Oncol. 2017;18:e367.
     PubMed    
     
     
     
123. MANAPOV F, Eze C
     Prophylactic cranial irradiation in small-cell lung cancer.
     Lancet Oncol. 2017;18:e366.
     PubMed    
     
     
     
124. RUSTHOVEN CG, Kavanagh BD
     Prophylactic cranial irradiation in small-cell lung cancer.
     Lancet Oncol. 2017;18:e365.
     PubMed    
     
     
     
125. DEL PAGGIO JC, Sullivan R, Schrag D, Hopman WM, et al
     Delivery of meaningful cancer care: a retrospective cohort study assessing cost and benefit with the ASCO and ESMO frameworks.
     Lancet Oncol. 2017;18:887-894.
     PubMed     Abstract available
     
     
     June 2017
126. BROWER V
     Atezolizumab in advanced non-small-cell lung cancer.
     Lancet Oncol. 2017 Jun 22. pii: S1470-2045(17)30504.
     PubMed    
     
     
     
127. FAIVRE-FINN C, Snee M, Ashcroft L, Appel W, et al
     Concurrent once-daily versus twice-daily chemoradiotherapy in patients with limited-stage small-cell lung cancer (CONVERT): an open-label, phase 3, randomised, superiority trial.
     Lancet Oncol. 2017 Jun 19. pii: S1470-2045(17)30318.
     PubMed     Abstract available
     
     
     
128. FIETKAU R
     Which fractionation of radiotherapy is best for limited-stage small-cell lung cancer?
     Lancet Oncol. 2017 Jun 19. pii: S1470-2045(17)30439.
     PubMed    
     
     
     
129. SHAW AT, Kim TM, Crino L, Gridelli C, et al
     Ceritinib versus chemotherapy in patients with ALK-rearranged non-small-cell lung cancer previously given chemotherapy and crizotinib (ASCEND-5): a randomised, controlled, open-label, phase 3 trial.
     Lancet Oncol. 2017 Jun 8. pii: S1470-2045(17)30339.
     PubMed     Abstract available
     
     
     May 2017
130. SHAVERDIAN N, Lisberg AE, Bornazyan K, Veruttipong D, et al
     Previous radiotherapy and the clinical activity and toxicity of pembrolizumab in the treatment of non-small-cell lung cancer: a secondary analysis of the KEYNOTE-001 phase 1 trial.
     Lancet Oncol. 2017 May 24. pii: S1470-2045(17)30380.
     PubMed     Abstract available
     
     
     
131. DAS M
     Brigatinib effective in ALK-positive non-small-cell lung cancer.
     Lancet Oncol. 2017 May 11. pii: S1470-2045(17)30342.
     PubMed    
     
     
     March 2017
132. GULLEY JL, Rajan A, Spigel DR, Iannotti N, et al
     Avelumab for patients with previously treated metastatic or recurrent non-small-cell lung cancer (JAVELIN Solid Tumor): dose-expansion cohort of a multicentre, open-label, phase 1b trial.
     Lancet Oncol. 2017 Mar 31. pii: S1470-2045(17)30240.
     PubMed     Abstract available
     
     
     
133. TAKAHASHI T, Yamanaka T, Seto T, Harada H, et al
     Prophylactic cranial irradiation versus observation in patients with extensive-disease small-cell lung cancer: a multicentre, randomised, open-label, phase 3 trial.
     Lancet Oncol. 2017 Mar 23. pii: S1470-2045(17)30230.
     PubMed     Abstract available
     
     
     
134. SLOTMAN BJ
     Time to reconsider prophylactic cranial irradiation in extensive-stage small-cell lung cancer?
     Lancet Oncol. 2017 Mar 23. pii: S1470-2045(17)30193.
     PubMed    
     
     
     February 2017
135. SCOTT JG, Berglund A, Schell MJ, Mihaylov I, et al
     A genome-based model for adjusting radiotherapy dose (GARD): a retrospective, cohort-based study.
     Lancet Oncol. 2017;18:202-211.
     PubMed     Abstract available
     
     

Thank you for your interest in scientific medicine.

AMEDEO Lung Cancer is free of charge. This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim. Design: